Rein Therapeutics, Inc. Common Stock
RNTX
About: Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
Employees: 11
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
2.28% more ownership
Funds ownership: 27.77% [Q1] → 30.05% (+2.28%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]
8% less funds holding
Funds holding: 39 [Q1] → 36 (-3) [Q2]
10% less capital invested
Capital invested by funds: $10.6M [Q1] → $9.54M (-$1.1M) [Q2]
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
Financial journalist opinion
